Genvor Inc

NuritasBiotechIreland

70% match

Nuritas uses a proprietary AI platform to discover, validate, and supply natural peptide ingredients for oral and topical health and wellness formulations. The company serves health and wellness brands by providing clinically-backed ingredients and custom peptide discovery services.

General BioBiotech

68% match

General Biotechnologies develops programmable synthetic biology platforms that use edible microbes to manufacture and deliver peptide therapeutics. The company primarily serves the pharmaceutical industry by reformulating discontinued peptide drugs into low-cost, needle-free oral medications and providing field-deployable biomanufacturing kits.

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Meddenovo Drug DesignBiotechnologyFrance

65% match

Meddenovo Drug Design is a Lyon, France-based biotechnology company operating at the intersection of AI and life sciences to build advanced computational technologies for peptide drug discovery.

VilyaBiotechUnited States

64% match

Launched in 2022 and headquartered in Seattle, Washington, Vilya is an AI peptide company co-founded by scientists from the Institute of Protein Design. The company uses artificial intelligence and synthetic biology to design novel macrocycle therapeutics inspired by nature.

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.